<DOC>
	<DOCNO>NCT00290953</DOCNO>
	<brief_summary>To demonstrate increase overall survival patient newly diagnose extend stage small cell lung cancer treat SR48692 versus placebo , initial response ( complete partial response stable ) first line cisplatin plus etoposide . Primary objective : comparison overall survival patient control arm meclinertant arm . Secondary objective : comparison progression free survival , time progression , clinical benefit , quality life , toxicity safety patient control arm meclinertant arm .</brief_summary>
	<brief_title>Evaluation Overall Survival Meclinertant Versus Placebo After First Line Chemotherapy With Cisplatin + Etoposide</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Pathological diagnosis : Histologically cytologically proven SCLC . Disease stage : extensive stage Measurable disease RECIST criterion require . Lesions present previously irradiate area nonmeasurable unless appear progress since completion radiation . Radiotherapy , applicable , must complete least 4 week treatment protocol subject must recover acute toxicity radiation . Recovered surgical procedure ( ) . Calculated creatinine clearance &gt; 55 ml/min use CockcroftGault formula : Cr Cl ml/min = ( 140age ) X ( weight kg ) X ( 1.0 men 0.85 woman ) / ( 72 X serum Cr mg/dl ) . Total bilirubin &lt; two time upper limit normal range institution SGOT/AST &lt; two time upper limit normal unless liver metastasis present . ANC &gt; 1.5 x 109/L platelet count &gt; 100 x 109/L . Age &gt; 18 year . Karnofsky Performance Status &gt; 70 % . Subjects prior malignancy , subject cure malignancy SCLC : ) alive without disease recurrence least 5 year date pathological diagnosis , b ) clinical expectation disease recurrence &lt; 5 % document medical record responsible physician , c ) receive platinumbased therapy . Subjects basal cell carcinoma carcinoma situ cervix may eligible adequately treated clinical expectation disease recurrence &lt; 5 % document medical record responsible physician . Infertile subject fertile subject use medically acceptable contraceptive throughout treatment period 3 month follow cessation treatment . Women childbearing potential must documentation negative , serum HCG pregnancy test . Subjects must make aware , enter trial , risk become pregnant fathering child . Signed write inform consent ( approve Ethics Committee ) obtain prior study entry . Limited disease . Symptomatic brain metastasis : patient brain and/or leptomeningeal metastasis computer tomography ( CT ) Magnetic Resonance Imaging ( MRI ) scan may include he/she asymptomatic neurologic exam receive corticosteroid therapy control symptom . Concurrent active cancer , include cancer stable adjuvant therapy . Prior immunotherapy , biological therapy chemotherapy SCLC . Radiotherapy : Prior radiation nonsymptomatic nonlifethreatening sites.Prior radiation therapy potential indicator lesion . Prior radiation therapy indicator lesion allow . Class III IV congestive heart failure accord New York Heart Association Classification . History allergic reaction appropriate diuretic antiemetic ( e.g. , 5HT3 antagonist ) administer conjunction protocoldirected chemotherapy . Uncontrolled intercurrent illness . Lactating pregnant woman . Received investigational drug within 30 day begin treatment study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Metastases</keyword>
</DOC>